

RECEIVED
CENTRAL FAX CENTER
MAY 09 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Laura S.L. GAETA et al.	Art Unit:	1639
Appln. No.: 10/649,138	Examiner:	Epperson, Jon D
Filed: August 26, 2003	Confirm. No.:	8797
Title: NOVEL AMYLIN AGONIST PEPTIDES AND USES THEREFOR (Amended)	Atty Docket No.	248/182 CON

TERMINAL DISCLAIMER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Dear Sir:

I, Karen R. Zachow, Ph.D., agent of record of Amylin Pharmaceuticals, Incorporated, 9360 Towne Centre Drive, San Diego, California 92121, represent that Amylin is the assignee of the entire right, title and interest, by assignment of the parent application encompassing continuation and divisional applications, which was recorded in the Patent and Trademark Office at Reel 015293, Frame 0487, of application Serial No. 07/794,266, filed November 19, 1991, for "Novel Amylin Agonist Peptides and Uses Therefor."

I hereby disclaim the terminal part of any patent granted on the above identified application, which would extend beyond the expiration date of the full statutory term defined in 35 USC §154 to §156, and §173 as presently shortened by any terminal disclaimer, of U.S. Patent No. 5,998,367, and hereby agree that any patent so granted shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to said U. S. Patent No. 5,998,367, this agreement to run with any patent granted on the above identified application and to be binding upon the grantee of such patent and its successors and assigns.

05/10/2006 HGUTEMA1 00000045 010535 10649138
03 FC:2814 65.00 DA

USSN 10/649,138
Atty Docket No. 248/182 CON
Page 2

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156, and §173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Please debit the amount of \$65.00 (small entity) for the payment of the Terminal Disclaimer fee under 37 CFR §1.20(d) to Applicants' deposit account number 010535 referencing Docket No. 248/182 CON. If any other fee should become due or credit become payable during the pendency of these proceedings, however, the Examiner is authorized to charge or credit the same to deposit account number 010535.

Date: 9 May 2006

Respectfully submitted,

AMYLIN PHARMACEUTICALS, INC.


Karen R. Zachow, Ph.D.
Reg. No. 46,332

Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, California 92121
Phone (858) 552-2200
Facsimile (858) 552-1936